Free Trial
NASDAQ:PRQR

ProQR Therapeutics Q1 2024 Earnings Report

ProQR Therapeutics logo
$1.74 +0.04 (+2.35%)
Closing price 04:00 PM Eastern
Extended Trading
$1.58 -0.16 (-8.91%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProQR Therapeutics EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

ProQR Therapeutics Revenue Results

Actual Revenue
$4.83 million
Expected Revenue
$3.31 million
Beat/Miss
Beat by +$1.52 million
YoY Revenue Growth
N/A

ProQR Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

ProQR Therapeutics' Q1 2025 earnings is scheduled for Thursday, August 14, 2025

Earnings Documents

ProQR Therapeutics Earnings Headlines

Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More ProQR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProQR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProQR Therapeutics and other key companies, straight to your email.

About ProQR Therapeutics

ProQR Therapeutics (NASDAQ:PRQR) N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

View ProQR Therapeutics Profile

More Earnings Resources from MarketBeat